6
GenScript Sets Up State-Of-Art Manufacturing Facility in Singapore to Strengthen Manufacturing Capability

GenScript Sets Up State-Of-Art Manufacturing Facility in Singapore to Strengthen Manufacturing Capability


GenScript Biotech Corporation (Stock Code: 1548.HK), the world's leading life science research tools and services provider, today announced the opening of more than 30,000-square-feet facility for highly automated protein and gene preparation services.  The state-of-the-art site marks a significant expansion of the company's advanced protein and gene platforms, and is designed to provide high quality, fast-turnaround on products required for new vaccines and therapeutics development and innovations in life sciences. Supported by the Singapore’s Economic Development Board (EDB), the new production site will support the Asia Pacific region and complements the current production sites in the United States and China.

The opening ceremony was held on a virtual setting inaugurated by Minister of State for Trade and Industry, and Culture, Community and Youth, Mr Alvin Tan and accompanied by Senior Vice President and Head, Healthcare, Singapore Economic Development Board (EDB), Ms Goh Wan Yee. During the ceremony, GenScript and A*STAR Diagnostics Development Hub signed on a memorandum of understanding (MoU) to explore the possibility of collaborations for the purposes of building manufacturing capabilities in Singapore.

The new manufacturing facility occupies over 30,000 square feet space at Solaris@Kallang building. The cutting edge facility in Singapore features a high throughput platform and proprietary technology of GenScript’s protein production to provide higher yield with a shorter turnaround time. Together with an experienced scientific and commercial team, GenScript is committed to provide tailored and top notch service to the region. The capacity of the new facility could also be expanded to strengthen other business units to support cell and gene therapy and vaccine development in the region.

“This is a significant milestone for us as we strengthen our presence in the vibrant and innovative ecosystem in Asia Pacific, Singapore. The new manufacturing facility will be a regional innovation and excellence hub in Asia Pacific and increase productivity of custom protein manufacturing. With the new manufacturing plant, we will be able to foster stronger collaboration with partners, research institutes and biopharmaceutical companies across the Asia Pacific region.”

Johnson Wang

President of GenScript, Asia Pacific Division

GenScript Biotech Corporation

“Singapore the home to GenScript’s Asia Pacific headquarters, it is also a strategic location for us to expand our manufacturing capability to support the fast growing biotechnology industry. With the strong support from EDB, our new facility aims to be the center of a solid regional network to catalyze more collaboration, ultimately spurring more innovation and breakthrough life science. This demonstrated GenScript’s commitment to build and develop the world leading enabling platform in serving science.”

Dr. Ray Chen

President of Life Science Group, GenScript Biotech Corporation

GenScript

“GenScript’s decision to set up its new production site and business hub in Singapore is testament to our robust manufacturing infrastructure, R&D and innovation ecosystem, strong base of biotech talent, as well as our excellent connectivity to the Asia-Pacific region. We look forward to working closely with GenScript to further expand its regional footprint, nurture local talent and drive better healthcare outcomes.”

Goh Wan Yee

Senior Vice President and Head, Healthcare

EDB

Press Release

10 February 2022

Contact Us Icon
Reach out to us for information on how we can facilitate your investment journey
Subscribe Icon
The latest business insights and news delivered to your inbox
Subscribe now